SPOTLIGHT: Protez raises $15M
Protez Pharmaceuticals of Malvern, Pennsylvania, has raised $15 million in its second round of venture capital. Protez intends to use the proceeds from the financing to accelerate development of its lead compound SMP-601, an injectable antibiotic. Release
More stories about Venture Capital
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
